U.S. judge rejects Bayer bid to block Johnson & Johnson prostate cancer drug claims [BNN Bloomberg (Canada)]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: BNN Bloomberg
In a Friday night decision, U.S. District Judge Dale Ho in Manhattan said Bayer did not show it was likely to succeed on the merits of its claims, which included that Johnson & Johnson's campaign for its drug Erleada caused irreparable harm and threatened to erode trust in Bayer's own drug Nubeqa. Bayer sued Johnson & Johnson on Feb. 23, accusing it of falsely claiming that patients had a “51 per cent reduction in risk of death” if treated with Erleada instead of Nubeqa, based on testing that adhered to “rigorous” U.S. Food and Drug Administration standards. The German drugmaker said claims Erleada worked better were unreliable because most Nubeqa patients received their drugs off-label. It also said the FDA did not vet Johnson & Johnson's backward-looking, real-world analysis as a substitute for traditional clinical trials. In a 41-page decision, Ho said Johnson & Johnson's communications accurately represented its study's conclusions, and Bayer did not identify methodological
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- CFOs On the Move: Week ending April 17 [Yahoo! Finance]Yahoo! Finance
- U.S. judge rejects Bayer's bid to block Johnson & Johnson prostate cancer drug claims [Yahoo! Finance]Yahoo! Finance
- Barclays Raises Johnson & Johnson (JNJ) Price Target on Strong Pharma Momentum [Yahoo! Finance]Yahoo! Finance
- Citadel's chief people officer leaves the firm as hedge funds battle for talent [Business Insider]Business Insider
- Johnson & Johnson: Why I See Downside Ahead [Seeking Alpha]Seeking Alpha
JNJ
Earnings
- 4/14/26 - Beat
JNJ
Sec Filings
- 4/14/26 - Form 8-K
- 3/26/26 - Form SCHEDULE
- 3/18/26 - Form 13F-HR/A
- JNJ's page on the SEC website